Following a limited submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
Mepolizumab (Nucala®) is recommended as an option for restricted use within NHS Wales. Mepolizumab (Nucala®) is licensed as an add-on treatment for severe refractory eosinophilic asthma in adolescents and children aged 6 years and older. Mepolizumab (Nucala®) is restricted for use in a subpopulation of the licensed indication in line with the National Institute of Health and Care Excellence recommendation for the restricted use of mepolizumab for treating severe refractory eosinophilic asthma in adults (TA671). Mepolizumab (Nucala®) is not recommended for use within NHS Wales outside of this subpopulation. |
|||
|
|||
Medicine details |
|||
| Medicine name | mepolizumab (Nucala®) | ||
| Formulation | 100 mg powder for solution for injection | ||
| Reference number | 3750 | ||
| Indication | Add-on treatment for severe refractory eosinophilic asthma in adolescents and children aged 6 years and older. |
||
| Company | GlaxoSmithKline | ||
| BNF chapter | Respiratory system | ||
| Submission type | Limited | ||
| Status | Recommended with restrictions | ||
| Advice number | 0619 | ||
| NMG meeting date | 06/03/2019 | ||
| AWMSG meeting date | 10/04/2019 | ||
| Date of issue | 12/04/2019 | ||
| Date of last review | June 2022 | ||
| Commercial arrangement | PAS | ||
| Further information Technologies recommended by NICE that include a commercial arrangement (excel) Please refer to NICE TA671 for the recommendation on mepolizumab (Nucala®) for treating severe refractory eosinophilic asthma in adults. |
|||